GlassScriptPhysician profile
David J Black
NPI 1841400371
$11,986.39
in general payments reported to CMS, 2019-2025
33 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $947 · 2021: $2,081 · 2022: $976 · 2023: $1,855 · 2024: $2,291 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,377 · Education: $31.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,377.12 |
| Education | $31.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,155.18 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,495.86 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,493.50 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $921.17 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $879.56 | 2019-2025 | |
| Celgene Corporation | $573.00 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $545.64 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $328.43 | 2024-2025 | |
| Lilly USA, LLC | $282.06 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $249.69 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $243.39 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $215.37 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $211.44 | 2023-2025 | Dupixent |
| Allergan, INC. | $174.30 | 2019-2020 | |
| Madrigal Pharmaceuticals | $152.24 | 2025 | Rezdiffra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $148.26 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $134.53 | 2019-2021 | |
| Redhill Biopharma INC. | $131.93 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $107.87 | 2021-2023 | Rebyota |
| Qol Medical, LLC | $107.46 | 2019-2024 | Sucraid |
| Janssen Scientific Affairs, LLC | $87.96 | 2021 | |
| Ardelyx, INC. | $80.47 | 2023-2024 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $62.66 | 2024-2025 | Iqirvo |
| Organon LLC | $38.42 | 2023 | Hadlima |
| Ethicon US, LLC | $36.56 | 2023 | Endopath Xcel, Endopath, Echelon Circular |
| Celltrion USA INC. | $20.67 | 2023 | Yuflyma |
| Echosens North America, INC. | $19.03 | 2024 | Fibroscan |
| Ucb, INC. | $18.82 | 2020 | |
| Alfasigma USA, INC. | $17.21 | 2020 | |
| Biocon Biologics INC | $15.90 | 2025 | Yesintek |
| Intercept Pharmaceuticals, INC. | $15.16 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.